Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
PLoS One. 2023 Sep 8;18(9):e0291044. doi: 10.1371/journal.pone.0291044. eCollection 2023.
As a poly-ADP ribose polymerase (PARP) inhibitor, veliparib has been identified as a potential therapeutic agent for lung cancer. The present study aimed to conduct a systematic review of clinical trials investigating the efficacy and safety of veliparib for treating lung cancer.
PubMed, Scopus, the Web of Science, and Google Scholar were systematically searched up to October 30, 2022. Only randomized controlled trials (RCTs) evaluating the efficacy or safety of veliparib in the treatment of lung cancer patients were included. Studies were excluded if they were not RCTs, enrolled healthy participants or patients with conditions other than lung cancer, or investigated therapeutic approaches other than veliparib. The Cochrane risk-of-bias tool was used for quality assessment.
The seven RCTs (n = 2188) showed that patients treated with a combination of veliparib and chemotherapy had a significantly higher risk of adverse events, when compared to the control arm. There was no statistically significant difference in overall survival (OS) between those treated with veliparib plus chemotherapy and those receiving the standard therapies. Only two trials demonstrated an improvement in progression-free survival (PFS), and only one study found an increase in objective response rate (ORR). Furthermore, adding veliparib to standard chemotherapy showed no benefit in extending the duration of response (DoR) in any of the studies.
Only a small number of studies have found veliparib to be effective, in terms of improved OS, PFS, and ORR, while the majority of studies found no benefit for veliparib over standard treatment.
聚 ADP 核糖聚合酶（PARP）抑制剂维利帕尼已被确定为治疗肺癌的潜在治疗药物。本研究旨在对评估维利帕尼治疗肺癌的疗效和安全性的临床试验进行系统评价。
系统检索了 PubMed、Scopus、Web of Science 和 Google Scholar，检索时间截至 2022 年 10 月 30 日。仅纳入评估维利帕尼治疗肺癌患者的疗效或安全性的随机对照试验（RCT）。排除非 RCT、纳入健康参与者或非肺癌患者的研究，以及研究其他治疗方法的研究。采用 Cochrane 偏倚风险工具进行质量评估。
7 项 RCT（n=2188）表明，与对照组相比，接受维利帕尼联合化疗的患者发生不良事件的风险显著增加。与接受标准治疗的患者相比，接受维利帕尼联合化疗的患者总生存期（OS）无统计学差异。只有两项试验显示无进展生存期（PFS）有所改善，只有一项研究发现客观缓解率（ORR）有所提高。此外，在任何一项研究中，添加维利帕尼到标准化疗中都没有延长缓解持续时间（DoR）。
只有少数研究发现维利帕尼在改善 OS、PFS 和 ORR 方面有效，而大多数研究发现维利帕尼与标准治疗相比没有获益。
